News | January 04, 2013

Biotronik Home Monitoring Reduces Inappropriate ICD Shocks by 52 Percent

ECOST trial results published in European Heart Journal

Biotronik Home Monitoring ECOST Clinical Trial ICDs

January 4, 2013 — Biotronik announced that the European Heart Journal has published the clinical results of the ECOST trial (Effectiveness and Cost of ICD Follow-Up Schedule with Telecardiology). The randomized controlled study evaluated the safety and efficacy of Biotronik Home Monitoring compared with standard in-office follow-up visits for patients with implantable cardioverter-defibrillators (ICDs).

Results from ECOST provide pioneering scientific evidence that continuous remote monitoring with Biotronik Home Monitoring reduces inappropriate shocks, may improve battery longevity in long-term follow-up of patients implanted with an ICD and is as safe as, sometimes even safer than standard in-office follow-ups. This outcome is consistent with previous findings from studies such as the landmark TRUST trial.[1,2]

ECOST is a prospective multicenter clinical trial designed to examine the safety and efficacy of remote monitoring of ICD patients with Biotronik Home Monitoring over 27 months. The study analyzed 433 patients from 43 sites throughout France who were randomly assigned to home monitoring follow-up or standard in-office care. The 221 home monitoring patients (the active group) were seen in the ambulatory department once per year, unless home monitoring reported a technical or clinical event requiring an in-office visit. The 212 control group patients underwent in-office visits every six months.

During a two-year period, the overall number of delivered shocks in the home monitoring group were 71 percent lower than in the control group — a significant decrease. Furthermore, the proportion of patients who received inappropriate shocks was 52 percent lower in the home monitoring group than in the control group. While some remote monitoring technologies can drain the device battery in the long term, daily BIOTRONIK Home Monitoring retains ICD battery life: ECOST showed a 76 percent reduction in the number of capacitor charges for the Biotronik Home Monitoring group (499 vs. 2081), resulting in extended device longevity.

“The ECOST trial results prove Biotronik Home Monitoring reduces inappropriate shocks in patients and also positively extends the ICD’s battery longevity,” said Professor Salem Kacet, principal investigator of the ECOST study. “This advanced technology is very important for the observation of arrhythmias and early adaptation of ICD therapy. Patients benefit from the reduced risk of inappropriate shocks — which can be a very unpleasant experience — and need ICD replacement less frequently.”

For more information: www.biotronik.com

References

1 Varma et al., Circulation, 2010, 122, 325–332.

2 Varma et al., Circ Arrhythm Electrophysiol, 2010, 3:428–436.

Related Content

A 3-D rendering created from the chest CT scan of a 41-year-old coronavirus patient in China showing ground-glass opacities in several areas of the lungs from the coronavirus pneumonia. This was from one of the first medical imaging studies published on COVID-19 in the journal Radiology. #coronavirus #COVID2019 #COVID19 #2019nCoV

A 3-D rendering created from the chest CT scan of a 41-year-old coronavirus patient in China showing ground-glass opacities in several areas of the lungs from the coronavirus pneumonia. This was from one of the first medical imaging studies published on COVID-19 in the journal Radiology. 

Feature | Cardiovascular Clinical Studies | February 20, 2020 | Dave Fornell, Editor
February 20, 2020 — The American College of Cardiology (ACC) released a
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Overlay Init